Amarin Corporation plc

NASDAQ:AMRN

Biotechnology

Healthcare
$11.26 +1.84%

+$0.29 today

Market cap
$232.89M
Beta
0.82
P/E (TTM)
-9.9
EPS (TTM)
-$1.62
52W Low $12.30High $20.90

Volume 0.09M

Average 0.07M

AMRN Other Financing Activities

Financing cash flows not reported separately.

Amarin Corporation plcNASDAQ: AMRN

Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026

Other financing activities grows, but more slowly than its trailing trend

Q1 FY2026 other financing activities of $1.69M (cash outflow) rose 50.8% year over year, behind the +117.1% change in trailing-twelve-month other financing activities. Sequentially, it rose 1895.0% from the prior quarter. Over 3 fiscal years it compounded at +27.8% a year.

Context

  • Other financing activities amounted to 1.0% of revenue in FY2025, up 0.3 pp from a year earlier.
  • Other financing activities grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +50.8% toward the trailing-twelve-month pace of +117.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.69M+1895.0% QoQ
Last fiscal yearDec 2025
-$2.18M+38.4% YoY
LTMMar 2026
-$2.73M+117.1% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+50.8%——
1 year+38.4%——
3-year CAGR+27.8%——
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2025
(2.18M) USD
Year-over-year change
-38.4%

Other Financing Activities vs competitors

How AMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +117.1% is the 2nd highest of 8, against a peer median of +95.6%.
  • Other financing activities amounts to 1.3% of revenue for AMRN, versus a peer median of 3.2%.
AMRN Competitors
Other Financing Activities for AMRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLLSCellectis S.A.LTM Mar 2026$6.49M USD+95.6%—9.5%
AMRNAmarin Corporation plcLTM Mar 2026$2.73M USD+117.1%+27.8%1.3%
ALTAltimmune, Inc.LTM Mar 2026$717K USD+38.7%—1991.7%
ANROAlto Neuroscience, Inc.LTM Mar 2026$229K USD+141.9%——
LYELLyell Immunopharma, Inc.LTM Mar 2026$2K USD-300.0%-87.1%6.5%
ACIUAC Immune S.A.LTM Dec 2025CHF 1.03K CHF+100.2%—0.0%
SLNSilence Therapeutics plcLTM Mar 2026$0 USD——0.0%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%——
DBVTDBV Technologies S.A.LTM Mar 2026$0 USD—+249.6%—
KRROKorro Bio, Inc.LTM Mar 2026$0 USD——0.0%
ENGNenGene Holdings Inc.LTM Apr 2026$0 USD+100.0%——
Peer median (excluding AMRN) —+95.6%+81.3%3.2%

Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income7.73M(105.74M)(59.34M)(82.18M)(38.8M)
Depreciation & Amortization2.86M3.09M2.98M3.01M3.03M
Deferred Income Tax00000
Stock-Based Compensation00017.71M13.94M
Change in Working Capital(115.98M)(104.01M)51.27M36.17M32.28M
Accounts Receivables(8.34M)32.98M(2.33M)11.22M(3.83M)
Inventory(167.05M)(36.4M)56.34M105.44M34.96M
Accounts Payables51.51M(102.67M)(164.64K)(77.02M)14.54M
Other Working Capital7.9M2.07M(2.56M)(3.5M)(13.39M)
Other Non-Cash Items38.86M26.67M12M(5.73M)(3.71M)
Operating Cash Flow(66.53M)(179.98M)6.91M(31.03M)6.74M
Capital Expenditures2(2)(24.1K)20
Acquisitions (Net)4K0000
Purchases of Investments(290.16M)(81.58M)(215.93M)(278.78M)(200.94M)
Sales of Investments394.25M257.36M190.84M232.8M209.79M
Other Investing Activities00000
Investing Cash Flow104.09M175.18M(25.62M)(45.98M)8.85M
Debt Repayment00000
Common Stock Issued4.57M664.59K2.22M131.06K140.33K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(9.64M)(1.04M)(1.99M)(1.57M)(2.18M)
Financing Cash Flow(5.07M)(378.77K)230.89K(1.44M)(2.04M)
Effect of Forex Changes3.87K(3.2K)71.37K33.01K(31.6K)
Net Change in Cash32.49M(5.18M)(18.41M)(78.44M)13.52M
Free Cash Flow(66.53M)(179.98M)6.88M(31.02M)6.74M

Amarin Corporation plc

NASDAQ:AMRN

Intrinsic Alpha fair value

Locked

Current Price

$11.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.